Advaxis (ADXS) Receives Price Target

Advaxis (ADXS) : 5 investment research analysts covering Advaxis (ADXS) have an average price target of $23.6 for the near short term. The highest target price given by the Brokerage Firm to the stock is $26 and the lowest target is $20 for the short term. Analysts expect the variance to be within $2.3 of the average price.


Also, Barclays maintains its rating on Advaxis (NASDAQ:ADXS). The global brokerage major raises the current price target from $15 per share to $20 per share. Analysts at the Barclays have a current rating of Overweight on the shares. The rating by the firm was issued on August 3, 2016.

Advaxis (NASDAQ:ADXS): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $11.53 and $11.53 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.83. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.78, notching a gain of 2.17% for the day. The total traded volume was 537,516 . The stock had closed at $11.53 on the previous day.

Advaxis, Inc. is a United States-based clinical-stage biotechnology company. The Company is focused on developing various cancer immunotherapies that use the bodys natural immune system to redirect the immune response to kill cancer. Its Lm Technology is a cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen, and neutralizes regulatory T cells and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Its Lm Technology immunotherapy, axalimogene filolisbac (ADXS-HPV), targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase II in invasive cervical cancer, Phase I/II in head and neck cancer, and Phase I/II in anal cancer. It has preclinical program with immunotherapies in development for cancers and infectious diseases.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *